NEW YORK (GenomeWeb) – Just days after cutting the proposed price range for its stock in a planned initial public offering, Microlin Bio has once again slashed the proposed offering price for its shares by $2 to between $4.50 and $5.50.

As reported by Gene Silencing News, the company first filed to go public on the Nasdaq in February, disclosing that it hoped to get between $6 to $8 a share for 3.6 million shares total. A few months later, it raised that range to $10 to $12, with the goal of floating 2.7 million shares.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.